Cargando...
PDCT-02. COMBINED INHIBITION OF MTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN PRECLINICAL TESTING OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE
Pediatric low-grade glioma (PLGG) is the most common brain tumor of childhood. We and others have identified mTOR and MEK-pathway activation in PLGG. The dual mTORC1/2-inhibitor, TAK228, and the FDA approved MEK-inhibitor, trametinib, are promising candidates for targeted PLGG therapy. We treated fi...
Gardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216989/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.832 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|